Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
Pauline M. Ellerbroek(University Medical Center Utrecht), Leman Yel(Children's Hospital of Philadelphia), P. Martin van Hagen(Chulalongkorn University), Torsten Witte(Medizinische Hochschule Hannover), Vassilios Lougaris(University of Brescia), Katharina Fielhauer(Baxalta (United States)), Leif G. Hanitsch(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Barbara McCoy(Baxalta (United States)), András Nagy(University of Szeged), Jie Chen(Guangdong Medical College), Pieter van Paassen(Maastricht University Medical Centre)
Cited by 5
Related Papers
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
|The Lancet Rheumatology|2020|199
A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome
|Nature Communications|2021|166
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Respiratory Medicine|2022|143
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations
|Journal of Allergy and Clinical Immunology|2020|127